Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation

Eleonore Fröhlich*

Center for Medical Research, Medical University Graz, Stiftingtalstr 24, 8010 Graz, Austria

Abstract: Nanomaterials can get into the blood circulation after injection or by release from implants but also by permeation of the epithelium after oral, respiratory or dermal exposure. Once in the blood, they can affect hemostasis, which is usually not intended. This review addresses effects of biological particles and engineered nanomaterials on hemostasis. The role of platelets and coagulation in normal clotting and the interaction with the immune system are described. Methods to identify effects of nanomaterials on clotting and results from *in vitro* and *in vivo* studies are summarized and the role of particle size and surface properties discussed. The literature overview showed that mainly pro-coagulative effects of nanomaterials have been described. *In vitro* studies suggested stronger effects of smaller than of larger NPs on coagulation and a greater importance of material than of surface charge. For instance, carbon nanotubes, polystyrene particles, and dendrimers inferred with clotting independent from their surface charge. Coating of particles with polyethylene glycol was able to prevent interaction with clotting by some particles, while it had no effect on others and the more recently developed bio-inspired surfaces might help to design coatings for more biocompatible particles. The mainly pro-coagulative action of nanoparticles could present a particular risk for individuals affected by common diseases such as diabetes, cancer, and cardiovascular diseases. Under standardized conditions, *in vitro* assays using human blood appear to be a suitable tool to study mechanisms of interference with hemostasis and to optimize hemocompatibility of nanomaterials.

1. INTRODUCTION

Engineered nanoparticles (NPs) are used in a variety of applications that involve contact with the blood, such as targeted drug delivery, imaging, implants and sensors. Due to their ability to permeate epithelial barriers, particularly the air-blood barrier, NPs can reach the systemic circulation also by other routes of exposure. This contact may result in damage of erythrocytes (hemolysis), immunologic effects (uptake of NPs by monocytes, activation of complement, immunotoxicity), and in impairment of hemostasis. Although several NPs, for instance TiO_2 tubes or polystyrene platelets have been developed to influence hemostasis [1, 2], for most exposures an influence on hemostasis is unwanted.

Dys-regulation of normal clotting may result in life-threatening situations, such as disseminated intravascular coagulation (DIC), also termed consumption coagulopathy and defibrination syndrome. In DIC blood clots clog the vessels and shut off blood supply of organs [3]. This results in ischemic cell damage and hemolysis. Ensuing consumption of platelets and coagulation factors causes diffuse bleeding, which worsens organ damage. DIC is induced by pro-coagulants in the blood in sepsis, severe tissue injury, obstetric complications, malignancies, liver failure, respiratory distress syndrome, and vascular disorders and is accompanied by a high mortality of 40-80%.

Also NPs may influence clotting. Epidemiological data suggest that air pollutants, for instance particulate matter (PM) are responsible for decreased as well as increased coagulation [4] but animal exposures to particles of ≤2.5 μm size (PM2.5) so far did not show significant adverse effects on blood coagulation [5].

Endothelial factors, plasmatic coagulation and platelet function regulate clotting and NPs may act on all three aspects. This review will focus on non-intended (toxic) effects of NPs on plasmatic coagulation, platelet

*Address correspondence to this author at the Center for Medical Research, Medical University Graz, Stiftingtalstr 24, 8010 Graz, Austria; Tel: +43316385-73011; Fax: +43316385-73009; E-mail: Eleonore.froehlich@medunigraz.at

function, and thrombosis *in vivo*. Small size and cationic surface charge play an important role in cytotoxicity (for review see for instance [6]), the role of these parameters in coagulation has been studied less well. Therefore, literature data were analyzed with respect to the influence of size, surface charge, material, application route and coating on coagulation. The interaction of coagulation with the immune system was highlighted because most NPs influence immune function [7].

2. CLOTTING OF BLOOD (HEMOSTASIS)

Hemostasis, coagulation and clotting of blood, describe processes that prevent blood loss and bleeding. This process is regulated in the endothelial lining of the blood vessels and cellular (platelets) and soluble (plasma proteins) components from the blood.

Injury of blood vessels starts hemostasis by release of von Willebrand Factor (vWF) from endothelial cells lining the blood vessel and binding of platelets to the injured site. By contact with the injured vessel wall platelets are activated, aggregate and secrete activators to recruit other platelets. Release of Tissue Factor (TF) by endothelium and monocytes activates one of the pathways, the extrinsic pathway, of plasmatic coagulation. Extracellular matrix underneath the damaged endothelial layer, mainly collagen, binds factor XII and initiates the other pathway, the intrinsic pathway, of plasmatic coagulation. Formation of the platelet clot is often termed primary hemostasis with fibrin formation being secondary hemostasis. The process is very fast; platelets adhere to the vessel wall within 3 sec, aggregation occurs within 10 sec and fibrin formation is initiated after 5 min. After 2-3 days platelets cause clot retraction and pull the edges of the cut vessel wall together to induce healing. Normal hemostasis further includes fibrinolysis and resolution of the clot, which occurs in parallel to healing of the vessel wall.

2.1. Platelets (Thrombocytes)

These cellular components of blood clotting originate from megakaryoblasts in the bone marrow, have a round to oval shape, do not possess a nucleus and measure 2-4 μm in diameter [8]. Human platelets have a life span of about 10 days and normal blood contains 150,000-450,000 platelets/mm^3. Only 67% of all platelets circulate in blood, the rest is stored in the spleen. Platelets consist of a peripheral zone with glycoprotein receptors, a structural zone with contractive microtubules, and an organelle zone with alpha granules, dense granules and lysosomes. α-Granules are 10 times more

abundant than dense granules and contain large adhesive and healing proteins, hemostatic factors vWF, factor V, fibrinogen, angiogenic factors such as vascular endothelial growth factor (VEGF), angiogenin and antiangiogenic factors like for instance angiostatin and platelet factor 4 (PF-4) and β-thromboglobulin (β-TG) [9]. These granules also contain basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), stromal cell derived factor 1 (SDF1), proteases, particularly metalloproteinases 2 and 9 (MMP-2, MMP-9), necrotic factors such as tumor necrosis factor alpha and beta (TNF-α, TNF-β) and other cytokines. Dense granules contain small molecules such as ADP, serotonin, Ca^{2+}, and histamine. Platelet activation is an energy-dependent process and requires mitochondrial function and glycogen as energy source. Platelets are involved in surveillance of vascular integrity, formation of the hemostatic plug, formation of fibrin network and healing. Main steps of primary hemostasis are adhesion of platelets, release of mediators and aggregation of platelets. Collagen exposure or thrombin action results in secretion of ADP, serotonin, fibrinogen, lysosomal enzymes and β-TG from the platelets. Serotonin mediates aggregation and vasoconstriction, various molecules released from α-granules are important for clot formation and PDGF serves for healing. Platelet activation is induced by activation of surface receptor upon binding of fibrinogen, thromboxane A2 (TXA2), Thrombin, ADP, adrenaline, collagen, antibody complexes, vWF, podoplanin and growth arrest specific gene 6 (*GAS6*), while binding of prostaglandin I2 (PGI2) inhibits platelet activation. Binding to the receptors activates G-protein coupled and tyrosine kinase mediated pathways (Fig. **1A**). Tyrosine (Tyr)-kinase coupled receptors act through sarcoma family kinases (SFKs) and phosphoinoside-3 kinase (PI3K) (Fig. **1B**). Similar to the G-protein coupled receptors these receptors use diacylglyceride (DAG) and intracellular Ca^{2+} changes as downstream messengers (for more details the reader is referred to reviews on this topic *e.g.* [10-12]). Signaling by G-proteins presents a widely used cellular pathway and the different G-protein alpha subunit isoforms are coupled to specific downstream effectors. Platelets express Gq, G12/13, Gi/z and Gs isoforms, which, with the exception of Gs, are coupled to platelet activation. The downstream regulators are assigned to specific platelet functions; Gq acts by phosphoinositid-phospholipase C - beta (PLC-β) activation on granule secretion, integrin activation, aggregation and shape changes. Gi signaling supports activation by inhibition of cAMP synthesis. G13 signaling acts *via* myosin light chain phosphatase kinase (MLCK) on shape and gran-

Fig. (1). Overview of platelet surface receptors with their respective ligands (A) and the most important signaling pathways involved in platelet signaling (B). Abbreviations: AC, adenylate cyclase; cAMP, cyclic adenosylmonophosphate; CLEC-2, C-type lectin-like receptor 2; DAG, diacylglyceride; *GAS6*: growth arrest specific gene 6; IP, prostacyclin receptor; IP3, inositol-trisphosphate; MLCK, myosin light chain phosphatase kinase; MAPK, mitogen-activated protein kinase; PAR, protease-activated receptor; PLA2, phospholipase A2; SFK, sarcoma family kinase; TPa, thromboxane A2 receptor alpha; TXA2, thromboxane A2; vWF, von Willebrand factor.

ule secretion. Small molecules secreted from granules are mainly involved in the amplification of the response. Integrin αIIbβ3 signaling initiates changes from low affinity to activated state (inside-out-signaling). This change is associated to the binding of two proteins, talin and kindlin, to the cytoplasmic region of the receptor, thereby increasing its sensitivity. Outside-in-signaling, on the other side, leads to platelet spreading, stable adhesion of platelets, granule secretion, and clot retraction.

2.2. Plasmatic Coagulation

Plasmatic coagulation is classified in intrinsic and extrinsic pathway. In normal hemostasis the primary task of the extrinsic pathway is initiating hemostasis. The intrinsic pathway acts as 'executor' of blood clotting but can be activated separately by various triggers, typically natural and artificial surfaces (collagen, glass, silica), prekallikrein (Fletcher factor), high molecular weight kininogen (Fitzgerald factor), and factors XII and XI [13]. Plasmatic coagulation is regulated by in total 13 factors, termed I-XIII, which are proteins with the exception of IV (calcium). The cascades serve to increase the signal in the way that each factor activates, usually by proteolytic cleavage, another factor and leads to massive amplification of the signal. Many of these factors, Prothrombin (II), Christmas factor (IX), Stuart-Power factor (X), Plasma thromboplastin ante-

cedent (XI), and Hageman factor (XII) are serine proteases in their active forms. Fibrinogen (I) forms the fibrin network for stabilization of the initial clot consisting of platelets and is the end product of the cascade (Fig. **2**). Physiological anticoagulants are antithrombin III (AT) and activated protein C (PC). Factor X links extrinsic and intrinsic pathway while thrombin connects activation of plasmatic coagulation to activation of platelets and on the other side fibrin generation to fibrinolysis. Thrombin cleaves plasminogen to active plasmin, which breaks down the links between fibrin strands and initiates degradation of the clot. Furthermore, thrombin activates PC to its active form. On the other hand, thrombin stabilizes the clot by activating thrombin-activatable fibrinolysis inhibitor (TAFI).

Fibrinolysis is initiated by cleavage of plasminogen to plasmin and is controlled by locally released and systemic factors (Fig. **2B**). Activation is stimulated by tissue-type plasminogen activator (tPA) released from endothelial cells and urokinase-type plasminogen activator (uPA). The action of tPA and uPA is inhibited by plasminogen activator inhibitor 1 (PAI-1). Kallikrein and factors XIIa and XIa start not only the intrinsic pathway of coagulation but limit also clotting *via* activation of plasminogen. The hepatic proteins α2-antiplasmin and α2-macroglobulin inhibit activation of plasmin.

2.3. Interaction of Coagulation and Inflammation

Activation of the extrinsic pathway of coagulation perpetuates and amplifies the inflammatory response and protects the body against spread of infectious agent [14]. This interaction is intense in sepsis and in acute arterial thrombosis (rupture of vulnerable plaques) and consists in activation of coagulation and inhibition of fibrinolysis by the inflammation process and increased secretion of cytokines and expression of adhesion molecules on endothelial cells by the coagulation process (Fig. **3**).

Endothelial activation/dysfunction stimulates inflammation and coagulation due to secretion of procoagulants and antifibrinolytic compounds (vWF, TXA2, PAI-1). The first phase of endothelial activation includes shedding of adhesion molecules P-selectin (CD62P or GMP140), thrombin, heparin, AT, and thrombomodulin. Gene up-regulation of intercellular adhesion molecule-1 (ICAM-1), E-selectin (CD62E) and release of vWF, interleukin (IL) 8, platelet-activating factor (PAF) are part of the second phase of endothelial activation [15]. Main players in the inflammation-coagulation interaction from the coagula-

tion side include factor VIIa belonging to the extrinsic pathway, factors IX and X of the intrinsic pathway as well as thrombin and fibrin [16]. TF, P- and E-selectin, VCAM-1, ICAM-1 stimulate neutrophilic granulocyte and platelet adhesion and promote both processes. TNF-α, IL-1, and IL-6 secreted by vascular endothelial cells and inflammatory cells amplify the hemostatic response. Activated platelets secrete adhesion molecules (fibrinogen, vWF, GPIIb/IIIa, thrombospondin, P-selectin and vitronectin), coagulation factors (fibrinogen, factors V, VII, XI, and XII), and fibrinolysis inhibitor PAI-1. Furthermore, they release microparticles (expressing TF) to stimulate coagulation. The role of MPs in coagulation will be described in the section 'Action of biological particles on coagulation'. C-reactive protein (CRP), which can be secreted by injured blood vessels, up-regulates various endothelial adhesion molecules and induces release of IL-8 [17]. CRP inhibits platelet aggregation but induces their adhesion to endothelial cells and monocytes. CRP stimulates TF expression in monocytes, inhibits release of tPA and stimulates PAI-2 release from endothelial cells. By binding to activated platelets dissociation from the pentametic (pCRP) to monomeric (mCRP) form occurs. This conversion is important because pCRP has anti-inflammatory action, while mCRP acts pro-inflammatory and pro-thrombotic [18].

Thrombin, in addition to activation of platelets and conversion of fibrinogen to fibrin, also exerts pro-inflammatory effects by binding to protease-activated receptors (PARs) leading to up-regulation of monocyte chemotactic protein 1 (MCP-1), IL-6, IL-8, and macrophage migration inhibitory factor (MIF) by endothelial cells, platelets, and leukocytes.

Furthermore, the complement system, the most important acellular system of the unspecific immune system, intensely interacts with coagulation. Complement and coagulation display a lot of similarities: i) both cascades represent an innate defense against the invasion of external threats, such as microbia, ii) the reaction is locally restricted and very rapid, iii) most actors are serine proteases, iv) there is a tight regulation of the pathways with initiation, amplification and propagation, v) contact with foreign surfaces initiates the cascade and vi) restraint is achieved by inhibition of the actual enzyme activities and restricted binding of cascade compounds. Details on this interaction have been reviewed for instance by [19-21] and will be only cursorily addressed in this review. Main functions of the complement system are: opsonisation of pathogens, recruitment of inflammatory cells to induce elimination

Fig. (2). Factors of plasmatic coagulation cascade that lead to generation of the fibrin network (left) and regulators for fibrinolysis of the fibrin clot (right). Role of the specific factors to clotting (initiation, propagation and fibrin formation) is indicated. Boxes in darker shade surrounded by black lines indicate activated factors (suffix 'a'), while squares in lighter shades of the same color and surrounded by white lines indicate the respective non-activated factors. Left: TF in combination with factor VIIa start the coagulation cascade and lead to activation of factors IX and X. Xa induces the final step prior to fibrin formation. Right: Plasminogen is activated to plasmin by tPA and uPA and by factors XIa, XIIa, and kallikrein. The activation to plasmin is inhibited indirectly by PAI-1 and directly by α2-antiplasmin and α2-macroglobulin. The degradation of fibrin to its degradation products (D-dimers) can be inhibited by TAFI. Abbreviations: TF, tissue factor; AT, antithrombin III, HMWK, high molecular weight kininogen; tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor 1; TAFI: thrombin activatable fibrinolysis inhibitor; uPA: urokinase-type plasminogen activator. Black arrows indicate activation and red arrows stand for inhibition.

Fig. (3). Interplay of coagulation and inflammation. Inflammation-induced endothelial cell activation with secretion of cytokines and activation of the complement system in combination with activation of the coagulation cascade act synergistically (black arrow). Increased levels of TF start both processes. Inhibition is achieved by anticoagulation (blackberry box) and anti-inflammatory (violet box) factors. Abbreviation: AT, antithrombin III; CD62E, endothelial leukocyte adhesion molecule 1; CRP, C-reactive protein; Fibr.gen, fibrinogen; Fnlysis, fibrinolysis; ICAM, intercellular adhesion molecule-1; IL, interleukin; IL-1Ra, interleukin-1 receptor antagonist; MASP-2: mannan-binding lectin serine protease 2; PARs, protease-activated receptors; PC/APC, protein C/activated protein C; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TGF-ß, transforming growth factor beta.

of pathogens by phagocytosis or by cell lysis, and tuning of the immune response by stimulation of B- and T-cells. Activation of the complement system can occur *via* three pathways, the classical, the lectin and the alternative pathway. These pathways converge at the level of C3-convertase, which cleaves complement compound 3 (C3) and releases C3a and C3b [22]. C3a is a peptide mediator of inflammation and recruits phagocytes while C3b functions as opsonin and participates in the formation of C5-convertase. C5b cleaved from C5 by C5-convertase initiates the formation of the membrane attack complex, which integrates into the membrane of pathogens and induces their lysis. Interactions with coagulation occur at the level of C3. Thrombin, factors IXa, Xa and XIa, as well as kallikrein directly activate C3 [23]. Other mediators, such as kallikrein, AT, P-selectin, TAFI, TEPI and vWF are involved in coagulation and complement system [13]. Mannose-binding lectin (MBL) of the lectin pathway activates prothrombin while factor XIIa activates the classical pathway of complement activation. C3a and C5a induce exposure of P-selectin and production of TF, microparticles, cytokine and vWF by platelets. C5b-9, released from C5 upon cleavage activates platelets and stimulates cytokine secretion from endothelial

cells [13]. Fibrinolysis is linked to inflammation by AT, which could be degraded by proteases released from neutrophilic granulocytes. Degradation of AT antagonizes the normal effects of AT, namely the inhibition of thrombin, and of factors Xa and IXa, the reduced activation of pro-inflammatory cells, the decreased interaction of leukocytes with endothelial cells and the induction of PGI2 in endothelial cells by the AT-thrombin complex. PC activated by platelets together with its cofactor protein S inactivates factors Va and VIIIa. It also acts anti-inflammatory by inhibition of pro-inflammatory cytokines, mainly TNF-α, IL-1β, and IL-6, secreted by monocytes, inhibition of chemotaxis and adhesion of leukocytes to endothelial cells and reduced production of pro-inflammatory cytokines and adhesion molecule. Thrombomodulin belongs to the PC system and attenuates thrombin effects, namely platelet activation, attraction of monocytes, upregulation of leukocyte adhesion and activation of inflammatory cells [24]. The thrombin-thrombomodulin complex activates TAFI. Anti-inflammatory proteins, IL-4, IL-10, IL-1Ra, and TGF-β are additional factors in the feedback loop. C3a and C5a are inactivated by plasmin but, on the other hand, the action of plasmin on C3 and C5 proteolysis is stimulatory [23].

3. HOW TO ASSESS NANOPARTICLE EFFECTS ON HEMOSTASIS

Correct assessment of platelet function requires specific precautions regarding quality of the blood samples. Samples need to be obtained by clean venipuncture because ADP released upon hemolysis from erythrocytes activates platelets. Similar to patients prior to surgery [25], volunteers should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4-5 days because NSAIDs inhibit platelet function by blocking the formation of TXA2 [26]. These drugs also inhibit prostacyclin I2 synthesis by endothelial cells. Samples should be stored firmly capped to avoid CO_2 loss and, in general, analysis within 3h after collection is advised. Most importantly, samples should not be cooled because this inhibits the platelet response. Contact with glass causes activation of platelets in platelet rich plasma and is another cause for false results [27].

A series of assays can be used to identify NP effects on hemostasis. Platelet activity is assessed by determination of β-TG, PF-4 and serotonin using enzyme immunoassays (EIA). The most often used enzyme immunosorbant assay (ELISA) is based on the binding of marker-specific antibodies followed by detection of the binding by a secondary horseradish peroxidase labeled antibody followed by detection of peroxidase activity [28].

Changes of platelet membrane integrity can be identified by detection of lactate dehydrogenase in the supernatant with fluorescent or colorimetric assays. Flow cytometry is the ideal technique to quantify changes in Integrin alpha-IIb (CD41), PAC1 (activated GP IIb/IIIa) and P-selectin (CD62P) expression. Flow cytometry identifies platelets according to size and granularity (side and forward scatter). The degree of expression of the respective markers is determined by fluorescence of the labeled antibodies bound to the marker. Light aggregometry is used to identify platelet aggregation and measures light transmission in stirred platelet-rich plasma or washed platelets; higher light transmission indicates aggregation.

Measurement of activated partial thromboplastin time (aPTT, activated prothrombin time) and prothrombin time (PT, partial prothrombin time, Protime, Quick's time), Thrombin Time (Thrombin Clotting Time, TCT, TT) and Fibrinogen levels by automated analyzer are suggested to assess plasmatic coagulation [29]. aPTT and PT are assays for the activity of intrinsic and extrinsic pathway of the plasmatic coagulation, respectively. Platelet poor plasma produced from citrated blood samples is usually tested. PT is started by addition of tissue factor and calcium; aPTT with only phospholipid fraction of the tissue extract, kaolin and calcium. Prolonged clotting times in PT indicate decreased levels of factors VII, X, V, prothrombin, or fibrinogen. Deficiency of factors XII, XI, VIII, IX, X, prothrombin, and fibrinogen will lead to extended clotting times in aPTT. These clot-based assays are subjected to variations not only because they can also be performed manually instead of the automated way but also because the results depend on type of container, type of coagulant, assay compounds, collection and storage of the samples and the time between collection and analysis. aPTT and PT are also not very sensitive; a reduction of 50% of a given factor would not result in a prolonged PT and aPTT time [30]. Thrombin Time (Thrombin Clotting Time, TCT, TT) uses thrombin for induction of clotting. Clotting factors such as thrombin, tPA, uPA, factors IX, X and XII, can be determined based on the proteolytic action of Xa to cleave a chromogenic substrate. Finally, determination of D-dimer levels caused by fibrin degradation are useful for evaluation of fibrinolysis [31]. Prothrombin activation fragment (F1.2) serves as an index of *in vivo* thrombin generation resulting from activation of plasmatic clotting. F1.2 levels are frequently measured by ELISA. Thromboelastography (TEM® and ROTEM®) give more detailed information on clotting by measurement of time to form the fibrin clot, strength of the clot and time to lyse the fibrin clot in whole blood samples. Citrated blood is re-calcified and rotated in a cup containing a pin, which moves relative to the cup through an angle of 4°45'. Movement can either be initiated by the cup (TEM) or by the pin (ROTEM). Upon clotting fibrin strands form between cup and pin and this signal is analysed.

The above-mentioned methods were established for the clinical evaluation of patients. They are not suitable to the same extent for the evaluation of NP effects for several reasons. NPs, especially colored NPs, are known for their interference with colorimetric, fluorescent and luminescent detection by different mechanisms [32-35].

Since coagulation is assessed in protein-containing media, such as plasma, the reactive particle surface has already been coated and interference with assay compounds is less likely. Interaction by color, however, may occur and interfere with measurements of ELISA assays [36]. Analysis by flow cytometry of platelet activation is not influenced by nanoparticles because the particles are too small to be detected by this method

unless the particles are fluorescent [37]. The use of appropriate assays including the right controls is essential for the evaluation of NPs on hemostasis. Some protocols have been developed by the Nanotechnology Characterization Laboratory at the National Cancer Institute-Frederick (Platelet Aggregation ITA-2 Version-1.0; Coagulation Assays, ITA-12 Version-1.0).

As mentioned before, aPTT and PT are relatively insensitive for small changes in coagulation. Also aggregometry, which has become a gold standard for the assessment of platelet aggregation might be not sensitive enough to assess the effects of NPs and a more recently developed technique based on Quartz Crystal Microbalance measurements appears to be more suitable [38].

4. ACTION OF PARTICLES ON COAGULATION

4.1. Effects of Biological Particles

Action of particles on coagulation is not restricted to engineered NPs. Two types of biological particles regulate coagulation and inflammation in the human body, cell-derived lipid vesicles (microparticles/exosomes) and calcium phosphate shell particles. The cell-derived lipid vesicles are classified according to their provenience and size into microparticles (MPs) and exosomes. MPs are derived from the plasma membrane in sizes of 0.1-1 μm, while exosomes originate from intracellular membranes and typically measure 40-100 nm [39]. Both types of particles are thought to be important for intercellular communication by transfer of proteins, mRNA and micro RNA (miRNA). The majority (>80%) of MPs circulating in the blood of healthy individuals are derived from platelets; endothelium-derived MPs represent 5-15%. Leukocytes are additional sources for these particles, which link coagulation, inflammation and angiogenesis. Stimulation of platelets with thrombin or shear stress induces production of MPs. Platelet-derived MPs have a life span of 10-30 min and have 50-100 fold higher pro-coagulant properties than identical surface on activated platelets. Endothelial cells release MPs after stimulation with TNF-α, Lipopolysaccharide (LPS), and oxidized low-density lipoproteins. The content of PAF, amyloid precursor protein (APP), Ca^{2+}-dependent protease, calpain, arachidonic acid and phospholipids, and cytokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) is linked to their pro-inflammatory action [40]. Leukocyte-derived MPs can inhibit coagulation by expression of TAFI on their surface. Monocyte-derived MPs also express the endothelial cell protein C receptor (EPCR), thereby promoting

the activation of PC by the thrombin (IIa)-thrombomodulin (TM) complex. Activated PC subsequently inactivates factors Va and VIIIa [41]. Procoagulant effects of MPs are caused by binding of coagulation factors, mainly factors VII, IX, X, and prothrombin to the negatively charged phosphatidylserine on their surface [42] but MPs can also serve as contact membranes for the activation of fibrinolysis [43]. Fibrinolysis can occur when MPs derived from endothelial cells bearing uPA/urokinase-type plasminogen activator receptor (uPAR) get into contact with plasminogen that has been bound to platelets.

The second type of biological particles is described as vesicles surrounded by a calcium phosphate shell. These particles are <500 nm, circulate in the blood, and appear to prevent coagulation [44]. Arteriosclerotic plaques, kidney and prostate stones, ovarian cancer, and altered mitral valves are potential sources for these particles. Agonist-induced platelet activation, induced by thrombin receptor activator peptide or by convulxin (activator of the collagen receptor) is inhibited by these particles. Since diseases with higher circulating levels of these particles are accompanied by hyper-coagulate state generation of these particles might be a reaction to guarantee normal hemostasis.

Engineered NPs are usually not wanted to affect hemostasis and testing for cytotoxicity, hemocompatibility and interference with the immune system are part of the biocompatibility testing. *In vivo* studies allow the evaluation of all aspects of hemostasis, effects on endothelium, platelet and plasmatic coagulation, as well as potential action on the immune system, while mechanistic studies are only possible to a limited degree. Importantly, the influence of LPS as common contaminant of NP preparations cannot be assessed. LPS can initiate inflammatory responses and can also influence the surface charge of NPs and biasing interpretations of effects caused by particles with different surface charges [45].

4.2. *In Vivo* Effects Of Engineered NPs on Coagulation

The overview of Table **1** shows that promotion of clotting by NPs has been more frequently reported than inhibition of clotting. Effects caused by parenteral application (ia, iv, ip) were not stronger than those obtained by non-parenteral application (in, it, oral). This effect is surprising because particles entering the blood directly can act more potently than particles that have to cross an epithelial barrier prior to getting in contact with blood.

Table 1.   Action of nanoparticles *in vivo*. **Sizes of nanoparticles have been determined in different conditions (as produced and in the media in which they were applied).**

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Effects on Thrombus Formation	Reference
Carbon, metal and metal oxide NPs					
Silver (Ag)					
ia, mouse	15	no effect on platelet activation		no effect on induced thrombosis	[46]
it, rat	10-100			increased venous thrombosis	[47]
Carboxylated nanodiamonds					
iv, mouse	4-10			pulmonary thromboembolism	[48]
CdSe quantum dots					
CdSe, carboxylated>amine, iv, mouse	40	platelet aggregation (+ agonist)		pulmonary thromboembolism	[49]
Carbon nanotubes, single-walled (SWCNTs)					
ia, mouse	< 2 x 1000-5000	platelet activation and aggregation		increase of induced thrombosis	[50]
iv, rat	not given			increase of induced thrombosis	[51]
Carbon nanotubes, multi-walled (MWCNTs)					
Amidated and carboxylated, iv, mouse	26-31 x 490-580			no changes in platelet counts	[52]
Iron oxide (Fe$_2$O$_3$)					
it, rat	22>280		prolonged aPTT, PT		[53]
Polystyrene (PS)					
Carboxylated, ia, mouse	60			increase of induced artery occlusion time	[50]
aminated ia, mouse	60			decrease of induced artery occlusion time	[50]
aminated, carboxylated, neutral, it, hamster	60			no effect on induced thrombosis	[54]
aminated, ia, hamster	400			no effect on induced thrombosis	[54]
Silica (SiO$_2$), amorphous					
iv, rat	30		activation extrinsic pathway		[55]
ip, mouse	50>500	platelet aggregation	no effect on aPTT and PT	increased thrombosis	[56]

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Effects on Thrombus Formation	Reference
in, mouse	30, 70, 100, 300, 1000		activation intrinsic pathway		[57]
iv, mouse	70		interaction with factor XII	DIC	[58]
iv, mouse	100, 300, 1000			no DIC	[58]
ia, mouse	<200	no effect on activation		no effect on induced thrombosis	[46]
aminated, neutral **oral, mouse**	200>50			DIC	[59]
Titanium dioxide (TiO$_2$)					
rutile, **ia, mouse**	10 x 40	no effect on activation and aggregation		no effect on mesenterial artery occlusion time	[50]
Rutile nanorods **it, rat**	4-6	platelet aggregation			[60]
anatase, not rutile **ia, mouse**	<100	platelet aggregation		Increase od induced thrombosis	[46]
Zinc oxide (ZnO)					
ia, mouse	<110	no platelet activation		no effect on induced thrombosis	[46]
Biodegradable Nanoparticles					
Dendrimers					
amine G7 PAMAM **iv, mouse**	8.1		fibrinogen aggregates	DIC	[61]
Amine G6.5 PAMAM **oral, mouse**	8.5			DIC	[59]
carboxylated, hydroxylated **oral, mouse**	8.5			minimal DIC	[59]
Liposomes					
Anionic **iv, guinea pig**	not given		induction of clotting		[62]
Cationic, neutral **iv, guinea pig**	not given		no effects on coagulation		[62]
Cationic **iv, rat**	not given			thrombocytopenia	[63]

Size-dependency has rarely been studied in a systematic way. One data set described effects of differently sized SiO_2 particles with most prominent effects for 50-70 nm SiO_2 particles. However, another study suggested that the effect of 200 nm SiO_2 particles was stronger than that caused by 50 nm particles. Size-dependent effects have to be interpreted with caution because characterization was not performed in the same medium.

Consistently, dendrimers of cationic charge caused DIC while anionic particles did not. Also cationic PS particles caused more pronounced effects than anionic particles. This is in contradiction with liposomes and CdSe particles where anionic particles induced more clotting. Negatively charged surfaces are more expected to initiate thrombotic events because in physiological coagulation contact with anionic physiological surfaces (extracellular matrix) initiates clotting.

A strong contribution of inflammation for the induction of coagulation has been suggested in studies on silica particles. Intratracheal instillation of 2 μm crystalline SiO_2 particles and intraperitoneal injection of 50 nm and 500 nm amorphous silica particles were evaluated for inflammation and coagulation [56, 64]. Upon both routes of application, similar trends were reported on platelet activation and plasmatic coagulation and depletion of monocytes, macrophages and neutrophilic granulocytes reduced not only inflammation but also thrombosis. Problems in comparisons of different *in vivo* studies include low standardization of tail bleeding and thrombosis models and strain differences in the sensitivity to the thrombosis induction. Furthermore, different doses and different ways of blood collection were used in the studies.

Taken together *in vivo* studies do not allow a clear statement on the role of size and surface charge on clotting.

Several studies compared *in vitro* effects in human blood samples to action of NPs in rodents [47, 48, 50, 51]. Only in few studies *in vitro* effects were more pronounced than *in vivo* effects [52]. Differences between *in vitro* samples using human blood and rodent studies would not be surprising because of differences between murine and human coagulation. Mouse blood contains much lower levels of immunologically detectable circulating PAI-1 [65], 3 times greater platelet numbers and smaller (half the size) platelets than human blood [66]. While the ultrastructure of murine platelets is similar to human platelets in most respects, the response of murine platelet to agonists differs from that of humans. Murine platelets show no response to ristocetin and need higher levels of ADP for the induction of aggregation. These differences are reflected in the evaluation of NPs. Comparison of platelet aggregation induced by the same 50 nm SiO_2 particles showed that 5 μg/ml were efficient in causing a significant increase in murine platelets, while only much higher concentrations (100 μg/ml) significantly increased aggregation of human platelets [37, 67]. By using Rotation Thromboelastometry it appeared that human and ovine blood sample were more prone to coagulation than samples from pig, rats, or rabbits [68].

4.3. Effects of Engineered NPs *In Vitro*

In vitro assays can discriminate between particle effects on platelets and on plasmatic coagulation. NPs may activate platelets directly or interfere with agonist-induced activation. On the other hand, they can act *via* their surface and initiate activation of plasmatic coagulation or they can bind coagulation factors (Fig. **4**).

Effects of different particles are summarized in Table **2**.

Effects on platelet function have been studied more often than plasmatic coagulation. This might be due to the fact that plasmatic coagulation is usually determined by automated analysis, which is available mainly at hospitals. These organizations, on the other hand, have problems in testing experimental samples. When NPs activated plasmatic coagulation mainly the intrinsic pathway was affected, while only amidated carbon nanotubes (CNTs) activated the extrinsic pathway [52]. CNTs showed activation on platelets and plasmatic coagulation, while poly(lactic-co-glycolic acid) (PLGA) and Titanium dioxide (TiO_2)- based NPs had almost no effects on platelets and plasmatic coagulation. The majority of the studies reported platelet activation and stimulation of intrinsic coagulation pathway by polystyrene (PS) particles up to 400 nm. Similar to the *in vivo* studies particles generally affected platelets and plasmatic coagulation in a similar way. Exceptions were iron carbide particles that affected only plasmatic coagulation and platelet activation and cationic G7 PAMAM dendrimers that activated platelets but inhibited platelet-dependent thrombin generation [94, 115].

In vitro studies suggested that small particles might act differently from larger particles. Smaller silver (Ag) NPs inhibited platelet activation and plasmatic clotting, while larger ones activated both processes. A potential explication for the controversial effect could be the dif-

Fig. (4). Potential effects of NPs on hemostasis. Abbreviation: ⇑: increase; ⇓: decrease

Table 2.   **Effects of nanoparticles on clotting *in vitro*. Sizes of nanoparticles have been determined in different conditions (as produced and in the media in which they were applied). Data were obtained from exposure with human blood samples. Platelet activation obtained by dynamic and not in static exposure is marked by asterisk (*).**

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Reference
Carbon, metal and metal oxide nanoparticles				
Silver (Ag)				
	10-15	inhibition of platelet aggregation		[69]
	16	no effect on platelet aggregation (+/- agonist)	thrombin generation decreased, aPTT prolonged	[70]
	20	inhibition of platelet aggregation		[71]
	24		inhibition of intrinsic pathway	[72]
	30	platelet activation, *	XIIa-like activity, activation of clotting	[73]
	10-100	platelet activation and aggregation, *		[47]
	90-240	platelet activation	induction of clot formation	[74]
Boron phosphate (BPO₄), plain not folate	180-280	Platelet aggregation by plain, *		[75]
Gold (Au)				
solid	9	platelet activation		[76]
solid	5-30	inhibition of platelet aggregation (+/- agonist)		[77]
solid	18>68	platelet activation, *		[78]
solid	18	no effect on activation and aggregation, *		[38]
solid, cationic and anionic	30	no effect on platelet aggregation		[79]
solid	50	no effect on platelet aggregation (+/- agonist)		[80]
solid	30, 50		binding to fibrinogen; no effect on coagulation	[81]
solid	>60	inhibition of platelet aggregation (+/- agonist)		[77]
solid	<60	platelet aggregation (+ agonist)		[78]
shells	2-3	inhibition of platelet aggregation		[82]

(Table 2) contd…

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Reference
shells	15	platelet aggregation		[82]
shells	150	platelet aggregation		[82]
hollow spheres	63	no effect on platelet aggregation (+/- agonist)		[83]
Nanodiamonds, carboxylated	4-10	platelet aggregation		[48]
	5;100		no effect on PT and aPTT	[84]
CdTe, thioglycylic acid-, cystamine-capped	2.6-4.8	Platelet activation and aggregation, *		[85]
CdSe, cysteine-capped	15	platelet aggregation		[86]
C60				
composite	10	no effect on platelet activation (+ agonist), *		[87]
Polyhydroxylated C60	7	platelet aggregation (+ agonist)		[88]
Single-walled carbon nanotubes (SWCNTs)				
plain	not given	platelet aggregation		[51]
carboxylated> carboxylated+PEG	< 2	platelet aggregation	accelerated clot formation	[89]
Carboxylated> carboxylated+PEG	< 2	platelet aggregation		[90]
Multi-walled carbon nanotubes (MWCNTs)				
Plain	60-100 x 1000-2000	platelet aggregation, release of microparticles, *		[91]
carboxylated	not given	platelet aggregation		[51]
Carboxylated, long>short	10 x 223, 10 x 926	platelet activation	accelerated fibrin formation, decreased clot formation, and reduced clot hardness	[92]
amidated, long>short	10 x 223, 10 x 926	platelet activation	accelerated fibrin formation, decreased clot formation, and reduced clot hardness	[92]
Plain>carboxylated	15 x 1000-2000	platelet aggregation		[93]
carboxylated	26-31 x 490-580	platelet activation	intrinsic pathway activation	[52]
Amidated	26-31 x 490-580	platelet activation	extrinsic pathway activation	[52]
Iron (Fe)				
Iron carbide, carboxylated, IgG, ProtA coated	30	no effect on platelet activation, *	activation of clotting: IgG and ProtA>carboxylated	[94]
iron carbide, carbon coated	33		activation of clotting	[95]
Ferucarbotran (Resovist)	30-90	slight effect on activation, no effect on aggregation, *		[96]

(Table 2) contd…

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Reference
Fe_2O_3; Fe_3O_4	55-65; 20-30	no effect on platelet activation	no effect on clot formation	[74]
Fe_2O_3 coated with poly-vinyl pyridine	80		intrinsic pathway inhibition	[97]
Fe_3O_4@$nSiO_2$, heparin coated	100		no effect on PT and aPTT	[98]
Polystyrene (PS)				
carboxylated	26		no effect on intrinsic pathway	[99]
Carboxylated	24, 220		intrinsic pathway activation	[100]
aminated	24, 220		decreased thrombin generation by FXII, IX depletion	[100]
Neutral	20, 200	no effect on platelet aggregation		[93]
carboxylated, amidated	20, 200	platelet activation and aggregation, *		[101]
Aminated, not carboxy-lated	60	platelet activation and aggregation		[50]
neutral	60	no effect on activation and aggregation, *		[38]
Amidated	60-80	platelet aggregation		[102]
carboxylated	60-80	platelet activation and aggregation		[102]
Carboxylated, aminated, neutral	50, 100	platelet aggregation		[103]
carboxylated	220		intrinsic pathway activation	[99]
Anionic > cationic latex	300	platelet aggregation		[104]
neutral, latex	200-400	platelet aggregation		[105]
Silica (SiO_2)				
amorphous	15		no effect on PT and aPTT, clotting induced	[106]
Amorphous	10, 50, 150, 500	platelet activation, 10>50 nm		[37]
amorphous	30	no effect on activation, *	no effect on clotting time	[94]
Amorphous	50	platelet adhesion and aggregation, *		[107]
amorphous	10, 50	platelet activation, 10 not 50 nm, *		[38]
Amorphous, cationic and anionic	70, 232		induction of clotting	[108]
bare and PEGylated ORMOSIL	35, 45		factor XII activation, activation intrinsic pathway	[109]
Mesoporous, pluronic polymer capped	107, 149		no effect on PT and aPTT	[110]
Titanium dioxide (TiO_2)				
Rutile	10 x 40	no effect on activation and aggregation		[50]
rutile	20-160	no effect on activation	no effect on clot formation	[74]

(Table 2) contd…

Material	Size (nm)	Effect on Platelets	Effects Plasmatic Coagulation	Reference
zinc oxide (ZnO), cationic and anionic	70, 232		induction of clotting	[108]
Biodegradable Nanoparticles				
cetyl alcohol/polysorbate, +/- PEG, anionic	119, 133	inhibition of platelet aggregation		[111]
Dendrimers				
Amine G1-G4 PAMAM dendrimers	2.2-4.5		prolonged clotting time and decreased initial clotting velocity	[112]
carboxylated, hydroxylated, amine G3-G6 PAMAM dendrimers	3.1-7.5	platelet activation and aggregation, large amine, *		[113]
Amine G7 PAMAM dendrimers	8.1	platelet activation	platelet-dependent thrombin generation inhibited	[114]
Liposomes				
Cationic	not given	inhibition of platelet aggregation (+ agonist), no effect without		[115]
anionic, neutral	not given	no effect on platelet aggregation (-/+ agonist)		[115]
Cationic	180-200	platelet activation		[116]
Poly(lactic-co-glycolic acid), PLGA				
PLGA-macrogol and chitosan	100-500	no effect on platelet aggregation (+/- agonist)		[117]
Anionic PLGA and PLGA-chitosan	580-640	no effect on activation and aggregation, weak inhibition of aggregation (+ agonist)		[118]
PLGA-alendronate	200	no effect on platelet aggregation and activation		[119]
poly(ε-caprolactone) lipid-core nanocapsules, chitosan coated	476	no effect on platelet aggregation	no effect on PT and aPTT	[120]
Chitosan				
cationic	430-580	no effect on activation and aggregation, weak inhibition of aggregation (+ agonist), *		[118]
Chitosan, plain, PEG	140; 105	platelet activation of bare not of PEG-coated particles	no effect on PT and aPTT	[121]

ferent release of Ag$^+$ from these particles. It has been hypothesized that the induction of platelet aggregation by silver NPs in catheter coating is caused by collision of the platelets with silver ions [122]. In general, faster release is expected from the smaller NPs due to greater surface area but coating of the particles and electrolytes in the solution can influence this release [123]. Smaller 10 nm silica (SiO$_2$) particles showed stronger activation of platelets than 50 nm particles. Studies of solid gold (Au) particles appear to suggest that <20 nm particles induce platelet activation while larger (>30 nm) particles cause no effect but not all studies support this hypothesis. Effects of size were also noted for CNTs; long MWCNTs activated platelets stronger than shorter tubes [92].

Conflicting results were obtained when surface charge-dependent effects were compared. Most studies

on CNTs reported activation of platelets and coagulation for carboxylated and amidated particles. However, one study showed that cationic CNTs induced platelet activation more strongly and that these particles activated the extrinsic pathway of coagulation while the anionic ones activated the intrinsic pathway [52]. Cationic and anionic SiO_2 particles were evaluated for plasmatic coagulation, where particles of both charges induced clotting. Different results were obtained for cationic and anionic PS particles and different mechanisms were identified; anionic particles showed stronger platelet activation and activated the intrinsic pathway of plasmatic coagulation in some studies, whereas activation by cationic, not by anionic PS particles was reported in other studies [50]. Finally, some authors did not find any dependence on surface charge and reported activation of platelets for neutral, cationic and anionic PS particles [103]. Dendrimers showed platelet activation and inhibition of plasmatic coagulation. These opposite effects may contribute to DIC observed *in vivo*, where an over-activation of clotting results in depletion of coagulation factors. Studies on liposomes reported activation as well as inhibition of platelet function. Reasons for these disparate results comprise differences in size as well as in lipid composition. PGLA and chitosan particles in different composition excelled by lack of interference with platelet function and plasmatic coagulation.

The influence of surface charge is difficult to interpret because effective surface charge is rarely positive in physiological solution due to binding of proteins with negative charge. The interpretation of charge-dependent effects is further complicated by the fact that changes in surface charge can be accompanied by changes in hydrophobicity. Miyamoto *et al.* studied more and less hydrophobic latex polystyrene particles and found that the hydrophilic particles induced platelet aggregation to a lower extent than the hydrophobic ones [104]. Hydrophobic particles can interact more closely with the plasma membrane of cells [124] and this might result in platelet activation. It is also expected that coagulation factors bind to a higher extent to hydrophobic than to hydrophilic particles. These effects stimulate the immune system more strongly than hydrophilic particles. Furthermore, higher protein binding by hydrophobic particles may also cause a higher uptake by cells of the reticulo-endothelial system and influence the immune reaction this way. Hydrophilicity/-phobicity is rarely indicated in the studies. One reason for that might be the scarce availability of techniques to determine this surface property. Binding of hydrophobic dyes, for instance Bengal Rose, is only

suitable for more hydrophobic particles and was not able to discriminate between PS particles of different surface charge [125]. In addition to surface charge, surface roughness, crystallinity, porosity, and chemical composition have a great influence on hemostasis. A variety of techniques for instance atomic force microscopy (AFM), transmission and scanning electron microscopy (TEM, SEM), small angle x-ray scattering (SAXS), X-ray diffraction (XRD), Brunauer, Emmett, Teller method (BET), *etc.* are available to determine these parameters [126]. However, these data are not routinely assessed and comparison between the data obtained by different techniques is difficult.

Differences between *in vitro* studies could also be caused by use of different platelet preparations; washed platelets were used in few studies (for instance [51]) while the majority studied effects in platelet-rich plasma. The interaction with plasma proteins has been shown to decrease platelet activation [85]. Further differences included the use of dynamic exposure (stirring, shaker) *versus* static exposure. Table **2** suggests, however, that platelet activation was not linked to the exposure condition. Particles tested in flow and in static condition showed the same effect on platelet activation [85].

Several mechanisms have been postulated to explain the increased clotting in NP exposed cells. Denaturation of factor XII by larger SiO_2 particles but not by smaller particles has been postulated [127]. On the other hand, consistent with the experimental data, a higher degree of contact activation of factor XII has been described for 30-50 nm particles due to the greater access to the surface [57]. In one study SiO_2 particles induced the intrinsic pathway of coagulation, while in another study, silica NPs of slightly greater size activated the extrinsic pathway [58]. MWCNTs, depending on the surface charge, showed activation by different routes; activation of factor IX, activation related to factor XII, and activation of the plasmatic coagulation by platelet activation [52]. Activation of integrin αIIbβ3 signaling represented an important mechanism for the activation of platelets by PS, SWCNTs, MWCNTs, silica, C60 fullerenes and CdTe quantum dots as well as for the inhibition by Ag NPs [51, 69, 85, 103, 128]. Surface charge did not have a prominent effect on this activation [85, 103].

5. HOW TO PREVENT ADVERSE EFFECTS ON HEMOSTASIS

Biological effects usually are contributed to the binding of macromolecules, mainly proteins, from

physiological media [129]. Interference with the immune system has been linked to the degree of protein binding to particles and prevention of this binding can decrease unwanted biological effects [130]. Coating of NPs with bulky molecules, commonly PEG, poly(vinylalcohol) (PVA), ethylenediaminetetraacetate (EDTA), polyethylene oxide (PEO), dextran sulfate, decreases protein binding to NPs as well as phagocytosis [121]. These coatings have also been used to decrease interference with platelets and coagulation factors. PEGylated SWCNTs caused less platelet aggregation than uncoated carboxylated particles, which is consistent with the idea that prevention of protein binding decreases interference with hemostasis [89, 90]. Coating with PEG, however, was not successful for all materials. No effect of PEGylation was observed for Au particles and SWCNTs [52, 90, 131]. The relative inefficacy of PEGylation for SWCNTs was also seen in studies on complement activation and suggests that obtaining a sufficient coating of these particles may be difficult [132, 133]. Similarly, PEGylation of OR-MOSIL did not change the pro-coagulant effect of these particles [109, 111]. It appears that PEGylation of particles is not suitable for all particles and particle-specific coatings need to be developed. Coating with starch reduced platelet aggregation to iron oxide NPs [134]. A stealth formulation consisting of PEG and di-palmitoylphosphatidylcholine (DPPC) reduced platelet activation and inhibited agonist (ADP) induced activation of polymeric particles [135]. For the development of biocompatible NPs, recent strategies on bio-inspired particles could be extremely useful. Bio-inspired particles were able to fulfill specific roles in the organism. Hydrogels mimicking red blood cells regarding size, shape and surface charge showed less non-intended interaction with blood cells and removal by the reticulo-endothelial system [136]. Similarly, NPs with platelet shape and different surface coatings could interact with biological substrates in a controlled manner and polydopamine coated micro- and nanoparticles, in contrast to uncoated PS particles, did not influence platelet aggregation and activation [2, 137]. Furthermore, information obtained from biocompatibility of implant surfaces could be used for the design of NPs [138].

CONCLUSION

Activation of platelets and induction of intrinsic pathway of plasmatic coagulation are the common mechanisms for increased clotting induced by NPs. This mainly pro-coagulate action of NPs could be particularly dangerous for individuals suffering from hy-per-coagulate states linked to common diseases, such as diabetes mellitus, arteriosclerosis, cancer and obstructive pulmonary disease. Thromboembolism in cancer patients occurs 6 times more frequently than in healthy individuals [139]. Hyper-coagulation is due to transformation of macrophages into tumor-type macrophages, which activate angiogenesis and promote tumor cell proliferation by secretion of pro-coagulant cytokines. These macrophages also impair fibrinolysis by increased levels of uPA and PAI-1 and decrease of tPA concentrations. Arteriosclerotic lesions are thrombogenic due to release of TF by macrophages and smooth muscle cells. In addition, fibrinolysis is impaired due to increased levels of uPA and PAI-1 [140]. Insulin resistance in diabetes patients increases TF and factor VII production [141]. Increased blood levels of prothrombin, fibrinogen and PAI-1 in combination with glycosylation and oxidation of clotting factors facilitate clot formation. Pro-coagulant levels in diabetes patients are higher than in healthy controls [142]. Inflammatory processes in the respiratory tract are major promoters of coagulation in asthma patients [143]. Impaired function of the PC pathway in combination with increased activation of platelets can cause pulmonary thrombosis. In parallel, increased production of PAI-1 causes decreased fibrinolysis of the formed thrombi. Other respiratory diseases, for instance chronic obstructive pulmonary disease and cystic fibrosis, display the same prothrombotic changes and make patients more vulnerable to the effects of NPs. This assumption is supported by the higher incidence of thrombotic events in regions with increased concentrations of PM in the air [144], where individuals with pre-existing alterations of coagulation were more affected.

The correlation of hemostatic effects to particle parameters based on *in vitro* studies indicated some importance of size on platelet activation. *In vivo* studies, on the other hand, did not show a clear correlation of size or surface-charge to coagulation. The described effects were in part material-specific. It might be concluded that hydrophobicity and surface topology could be more relevant for coagulation than size and surface charge.

LIST OF ABBREVIATIONS

AC   = adenylate cyclase

AFM   = atomic force microscope

APC   = activated protein C

APP   = amyloid precursor protein

aPTT	=	activated partial thromboplastin time
AT	=	antithrombin III
BET	=	Brunauer, Emmett, Teller method
bFGF	=	basic fibroblast growth factor
C3	=	complement compound 3
cAMP	=	cyclic adenosylmonophosphate
CdSe	=	cadmium selenide
CLEC-2	=	C-type lectin-like receptor 2
CRP	=	C-reactive protein
DAG	=	diacylglyceride
DIC	=	disseminated intravascular coagulation
DPPC	=	dipalmitoylphosphatidylcholine
EDTA	=	ethylenediaminetetraacetate
EIA	=	enzyme Immunoassay
ELISA	=	enzyme linked immunosorbent Assay
EPCR	=	endothelial cell protein C receptor
F1.2	=	prothrombin activation fragment
GAS6	=	growth arrest specific gene 6
HMWK	=	high molecular weight kininogen
ia	=	intra-arterial
ICAM-1	=	intercellular adhesion molecule-1
IgG	=	immunoglobulin G
IL	=	interleukin
IL-1Ra	=	interleukin-1 receptor antagonist
in	=	intranasal
ip	=	intraperitoneal
IP	=	prostacyclin receptor
IP3	=	inositoltrisphosphate
it	=	intratracheal
iv	=	intravenous
LPS	=	lipopolysaccharide
MAPK	=	mitogen-activated protein kinase
MCP-1	=	monocyte chemotactic protein 1
MIF	=	macrophage migration inhibitory factor
miRNA	=	micro RNA
MLCK	=	myosin light chain phosphatase kinase
MMP	=	metalloproteinase
MPs	=	microparticles
MWCNTs	=	multi-walled carbon nanotubes
NP	=	nanoparticle
NSAIDs	=	non-steroidal anti-inflammatory drugs
PAF	=	platelet-activating factor
PAI-1	=	plasminogen activator inhibitor 1
PAMAM	=	Polyamidoamine
PAR	=	protease-activated receptor
PC	=	protein C
PEG	=	polyethylene glycol
PEO	=	polyethylene oxide
PF-4	=	platelet factor 4
PGI2	=	prostaglandin I2
PI3K	=	phosphoinoside-3 kinase
PLA2	=	phospholipase A2
PLC-β	=	phosphoinositide-phospholipase - beta
PLGA	=	poly(lactic-co-glycolic acid)
PM	=	particulate matter
ProtA	=	protein A
PS	=	polystyrene
PT	=	partial prothrombin time
RANTES	=	regulated on activation, normal T cell expressed and secreted
SAXS	=	small angle x-ray scattering
SDF-1	=	stromal cell derived factor 1
SEM	=	scanning electron microscope
SFK	=	sarcoma family kinase
SiO$_2$	=	silica
SWCNTs	=	single-walled carbon nanotubes
TAFI	=	thrombin-activatable fibrinolysis inhibitor
TEM	=	transmission electron microscope
TF	=	tissue factor
TFPI	=	tissue factor pathway inhibitor
TGF-β	=	transforming growth factor beta
TiO$_2$	=	titanium dioxide
TM	=	thrombin (IIa)-thrombomodulin
TNF-α	=	Tumor necrosis factor alpha
TP	=	thromboxane receptor

tPA   =   tissue-type plasminogen activator

TT   =   thrombin Time

TXA2   =   thromboxane A2

uPA   =   urokinase-type plasminogen activator

uPAR   =   urokinase-type plasminogen activator receptor

VCAM-1 =   vascular cell adhesion molecule 1

vWF   =   Willebrand Factor

XRD   =   X-ray diffraction

β-TG   =   β- thromboglobulin

CONFLICT OF INTEREST

The author confirms that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

REFERENCES

[1]   Roy, S.C.; Paulose, M.; Grimes, C.A. The effect of TiO_2 nanotubes in the enhancement of blood clotting for the control of hemorrhage. *Biomaterials,* **2007**, *28*(31), 4667-4672.

[2]   Anselmo, A.C.; Modery-Pawlowski, C.L.; Menegatti, S.; Kumar, S.; Vogus, D.R.; Tian, L.L.; Chen, M.; Squires, T.M.; Sen Gupta, A.; Mitragotri, S. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. *ACS Nano,* **2014**, *8*(11), 11243-11253.

[3]   Schafer, A. Hemorrhagic Disorders: DIC, Liver Failure, and Vitamin K Deficiency. In: *Goldman's Cecil Medicine*; Goldman, L., Schafer, A., Eds.; Elsevier Saunders: Philadelphia, **2011**.

[4]   Lippi, G.; Favaloro, E.J.; Franchini, M.; Guidi, G.C. Air pollution and coagulation testing: a new source of biological variability? *Thromb. Res.,* **2008**, *123*(1), 50-54.

[5]   Nadziejko, C.; Fang, K.; Chen, L.C.; Cohen, B.; Karpatkin, M.; Nadas, A. Effect of concentrated ambient particulate matter on blood coagulation parameters in rats. *Res. Rep. Health Eff. Inst.,* **2002**, (111), 7-29.

[6]   Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int. J. Nanomedicine,* **2012**, *7*, 5577-5591.

[7]   Fröhlich, E. Value of phagocyte function screening for immunotoxicity of nanoparticles *in vivo*. *Int. J. Nanomedicine,* **2015**, *10*, 3761-3778.

[8]   Andrews, R.K.; Berndt, M.C. Platelet physiology and thrombosis. *Thromb. Res.,* **2004**, *114*(5-6), 447-453.

[9]   Stalker, T.J.; Traxler, E.A.; Wu, J.; Wannemacher, K.M.; Cermignano, S.L.; Voronov, R.; Diamond, S.L.; Brass, L.F. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. *Blood,* **2013**, *121*(10), 1875-1885.

[10]   Senis, Y.A.; Mazharian, A.; Mori, J. Src family kinases: at the forefront of platelet activation. *Blood,* **2014**, *124*(13), 2013-2024.

[11]   Li, Z.; Delaney, M.K.; O'Brien, K.A.; Du, X. Signaling during platelet adhesion and activation. *Arterioscler. Thromb. Vasc. Biol.,* **2010**, *30*(12), 2341-2349.

[12]   Brass, L.F.; Tomaiuolo, M.; Stalker, T.J. Harnessing the platelet signaling network to produce an optimal hemostatic response. *Hematol. Oncol. Clin. North Am.,* **2013**, *27*(3), 381-409.

[13]   Conway, E.M., Reincarnation of ancient links between coagulation and complement. *J. Thromb. Haemost.,* **2015**, *13*(Suppl 1), S121-S132.

[14]   Levi, M.; van der Poll, T.; Buller, H.R. Bidirectional relation between inflammation and coagulation. *Circulation,* **2004**, *109*(22), 2698-2704.

[15]   Zhang, J.; Defelice, A.F.; Hanig, J.P.; Colatsky, T. Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. *Toxicol. Pathol.,* **2010**, *38*(6), 856-871.

[16]   Zoller, B.; Li, X.; Sundquist, J.; Sundquist, K. Autoimmune diseases and venous thromboembolism: a review of the literature. *Am. J. Cardiovasc. Dis.,* **2012**, *2*(3), 171-183.

[17]   Fay, W.P. Linking inflammation and thrombosis: Role of C-reactive protein. *World J. Cardiol.,* **2010**, *2*(11), 365-369.

[18]   Eisenhardt, S.U.; Habersberger, J.; Murphy, A.; Chen, Y.C.; Woollard, K.J.; Bassler, N.; Qian, H.; von Zur Muhlen, C.; Hagemeyer, C.E.; Ahrens, I.; Chin-Dusting, J.; Bobik, A.; Peter, K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. *Circ. Res.,* **2009**, *105*(2), 128-137.

[19]   Oikonomopoulou, K.; Ricklin, D.; Ward, P.A.; Lambris, J.D. Interactions between coagulation and complement--their role in inflammation. *Semin. Immunopathol.,* **2012**, *34*(1), 151-165.

[20]   Markiewski, M.M.; Nilsson, B.; Ekdahl, K.N.; Mollnes, T.E.; Lambris, J.D. Complement and coagulation: strangers or partners in crime? *Trends Immunol.,* **2007**, *28*(4), 184-192.

[21]   Amara, U.; Rittirsch, D.; Flierl, M.; Bruckner, U.; Klos, A.; Gebhard, F.; Lambris, J.D.; Huber-Lang, M. Interaction between the coagulation and complement system. *Adv. Exp. Med. Biol.,* **2008**, *632*, 71-79.

[22]   Murphy, K.; Travers, P.; Walport, M. *Janeway's Immunobiology.* 7th ed.; Garland Science;: New York **2008**.

[23]   Amara, U.; Flierl, M.A.; Rittirsch, D.; Klos, A.; Chen, H.; Acker, B.; Bruckner, U.B.; Nilsson, B.; Gebhard, F.; Lambris, J.D.; Huber-Lang, M. Molecular intercommunication between the complement and coagulation systems. *J. Immunol.,* **2010**, *185*(9), 5628-5636.

[24]   Margetic, S. Inflammation and hemostasis. *Biochem. Medica,* **2012**, *22*(1), 49-62.

[25]   Younan, M.; Atkinson, T.; Fudin, J. A practical approach to discontinuing NSAID therapy prior to a procedure. *Pract. Pain Manag.,* **2013**, *13*(10), 45-51.

[26]   Schafer, A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. *J. Clin. Pharmacol.,* **1995**, *35*(3), 209-219.

[27]   Harrison, P.; Mackie, I.; Mumford, A.; Briggs, C.; Liesner, R.; Winter, M.; Machin, S.; British Committee for Standards in, H. Guidelines for the laboratory investigation of heritable disorders of platelet function. *Br. J. Haematol.,* **2011**, *155*(1), 30-44.

[28]   Nix, B.; Wild, D. Data Processing. In: *Immunoassays, A Practical Approach*; Gosling, J., Ed.; Oxford University Press: Oxford, **2000**, pp. 239-261.

[29]   Evani, S.; Ramasubramanian, A. Hemocompatibility of Nanoparticles. In: *Nanobiomaterials Handbook*; Sitharaman, B., Ed.; CRC Press: Boca Raton, **2011**, pp 31_31-31_13.

[30]   Monroe III, D.; Hoffman, M.; Roberts, H. Molecular Biology and Biochemistry of the Coagulation Factors and Pathways of Hemostasis. In: *Williams Hematology*, 8th ed.; Kaushansky, K., Lichtman, M., Seligsohn, U., Beutler, E., Kipps, T., Prchal, J., Eds.; McGraw-Hill Companies: New York, **2010**.

[31]   Riley, R.; Tidwell, A.; Williams, D.; Bode, A.; Carr, M. Laboratory evaluation of hemostasis. http://www.pathology.vcu.edu/clinical/coag/Lab Hemostasis.pdf. [March 2015].

[32]   Fröhlich, E.; Meindl, C.; Pieber, T. Important issues in the cytotoxicity screening of nano-sized materials. *EURO-NanoTox Lett.,* **2010**, *1*, 1-6.

[33]   Kong, B.; Seog, J.H.; Graham, L.M.; Lee, S.B. Experimental considerations on the cytotoxicity of nanoparticles. *Nanomedicine: Nanotech. Biol. Med.,* **2011**, *6*(5), 929-941.

[34]   Kroll, A.; Pillukat, M.H.; Hahn, D.; Schnekenburger, J. Current *in vitro* methods in nanoparticle risk assessment: limitations and challenges. *Eur. J. Pharm. Biopharm.,* **2009**, *72*(2), 370-377.

[35]   Monteiro-Riviere, N.A.; Inman, A.O.; Zhang, L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. *Toxicol. Appl. Pharmacol.,* **2009**, *234*(2), 222-235.

[36]   Kroll, A.; Pillukat, M.H.; Hahn, D.; Schnekenburger, J. Interference of engineered nanoparticles with *in vitro* toxicity assays. *Arch. Toxicol.,* **2012**, *86*(7), 1123-1136.

[37]   Corbalan, J.J.; Medina, C.; Jacoby, A.; Malinski, T.; Radomski, M.W. Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. *Int. J. Nanomedicine,* **2012**, *7*, 631-639.

[38]   Santos-Martinez, M.J.; Inkielewicz-Stepniak, I.; Medina, C.; Rahme, K.; D'Arcy, D.M.; Fox, D.; Holmes, J.D.; Zhang, H.; Radomski, M.W. The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation. *Int. J. Nanomedicine,* **2012**, *7*, 243-255.

[39]   Burnier, L.; Fontana, P.; Kwak, B.R.; Angelillo-Scherrer, A. Cell-derived microparticles in haemostasis and vascular medicine. *Thromb. Haemost.,* **2009**, *101*(3), 439-451.

[40]   Owens, A.P. 3rd.; Mackman, N. Microparticles in hemostasis and thrombosis. *Circ. Res.,* **2011**, *108*(10), 1284-1297.

[41]   Angelillo-Scherrer, A. Leukocyte-derived microparticles in vascular homeostasis. *Circ. Res.,* **2012**, *110*(2), 356-369.

[42]   Markiewicz, M.; Richard, E.; Marks, N.; Ludwicka-Bradley, A. Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. *J. Aging Res.,* **2013**, *2013*, 734509.

[43]   Plawinski, L.; Angles-Cano, E. Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers. *Haematologica,* **2013**, *98*(7), e75-76.

[44]   Miller, V.M.; Hunter, L.W.; Chu, K.; Kaul, V.; Squillace, P.D.; Lieske, J.C.; Jayachandran, M. Biologic nanoparticles and platelet reactivity. *Nanomedicine,* **2009**, *4*(7), 725-733.

[45]   Ilinskaya, A.N.; Dobrovolskaia, M.A. Nanoparticles and the blood coagulation system. Part II: safety concerns. *Nanomedicine,* **2013**, *8*(6), 969-981.

[46]   Haberl, N.; Hirn, S.; Holzer, M.; Zuchtriegel, G.; Rehberg, M.; Krombach, F. Effects of acute systemic administration of TiO, ZnO, SiO, and Ag nanoparticles on hemodynamics, hemostasis and leukocyte recruitment. *Nanotoxicology,* **2015**, 1-9.

[47]   Jun, E.A.; Lim, K.M.; Kim, K.; Bae, O.N.; Noh, J.Y.; Chung, K.H.; Chung, J.H. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. *Nanotoxicology,* **2011**, *5*(2), 157-167.

[48]   Kumari, S.; Singh, M.K.; Singh, S.K.; Gracio, J.J.; Dash, D. Nanodiamonds activate blood platelets and induce thromboembolism. *Nanomedicine,* **2014**, *9*(3), 427-440.

[49]   Geys, J.; Nemmar, A.; Verbeken, E.; Smolders, E.; Ratoi, M.; Hoylaerts, M.F.; Nemery, B.; Hoet, P.H., Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge. *Environ. Health Perspect.,* **2008**, *116*(12), 1607-1613.

[50]   Bihari, P.; Holzer, M.; Praetner, M.; Fent, J.; Lerchenberger, M.; Reichel, C.A.; Rehberg, M.; Lakatos, S.; Krombach, F. Single-walled carbon nanotubes activate platelets and accelerate thrombus formation in the microcirculation. *Toxicology,* **2010**, *269*(2-3), 148-154.

[51]   Radomski, A.; Jurasz, P.; Alonso-Escolano, D.; Drews, M.; Morandi, M.; Malinski, T.; Radomski, M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. *Br. J. Pharmacol.,* **2005**, *146*(6), 882-893.

[52]   Burke, A.R.; Singh, R.N.; Carroll, D.L.; Owen, J.D.; Kock, N.D.; D'Agostino, R., Jr.; Torti, F.M.; Torti, S.V. Determinants of the thrombogenic potential of multiwalled carbon nanotubes. *Biomaterials,* **2011**, *32*(26), 5970-5978.

[53]   Zhu, M.T.; Feng, W.Y.; Wang, B.; Wang, T.C.; Gu, Y.Q.; Wang, M.; Wang, Y.; Ouyang, H.; Zhao, Y.L.; Chai, Z.F. Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. *Toxicology,* **2008**, *247*(2-3), 102-111.

[54]   Nemmar, A.; Hoylaerts, M.F.; Hoet, P.H.; Vermylen, J.; Nemery, B. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. *Toxicol. Appl. Pharmacol.,* **2003**, *186*(1), 38-45.

[55]   Liu, X.; Sun, J. Time-course effects of intravenously administrated silica nanoparticles on blood coagulation and endothelial function in rats. *J. Nanosci. Nanotechnol.,* **2013**, *13*(1), 222-228.

[56]   Nemmar, A.; Albarwani, S.; Beegam, S.; Yuvaraju, P.; Yasin, J.; Attoub, S.; Ali, B.H. Amorphous silica nanoparticles impair vascular homeostasis and induce systemic inflammation. *Int. J. Nanomedicine,* **2014**, *9*, 2779-2789.

[57]   Yoshida, T.; Yoshioka, Y.; Tochigi, S.; Hirai, T.; Uji, M.; Ichihashi, K.; Nagano, K.; Abe, Y.; Kamada, H.; Tsunoda, S.; Nabeshi, H.; Higashisaka, K.; Yoshikawa, T.; Tsutsumi, Y. Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. *Part. Fibre Toxicol.,* **2013**, *10*, 41.

[58]   Nabeshi, H.; Yoshikawa, T.; Matsuyama, K.; Nakazato, Y.; Arimori, A.; Isobe, M.; Tochigi, S.; Kondoh, S.; Hirai, T.; Akase, T.; Yamashita, T.; Yamashita, K.; Yoshida, T.; Nagano, K.; Abe, Y.; Yoshioka, Y.; Kamada, H.; Imazawa, T.; Itoh, N.; Kondoh, M.; Yagi, K.; Mayumi, T.; Tsunoda, S.; Tsutsumi, Y. Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. *Nanotechnology,* **2012**, *23*(4), 045101.

[59]   Greish, K.; Thiagarajan, G.; Herd, H.; Price, R.; Bauer, H.; Hubbard, D.; Burckle, A.; Sadekar, S.; Yu, T.; Anwar, A.; Ray, A.; Ghandehari, H. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. *Nanotoxicology,* **2012**, *6*(7), 713-723.

[60]   Nemmar, A.; Melghit, K.; Ali, B.H. The acute proinflammatory and prothrombotic effects of pulmonary exposure to rutile TiO$_2$ nanorods in rats. *Exp. Biol. Med.,* **2008**, *233*(5), 610-619.

[61]   Jones, C.F.; Campbell, R.A.; Brooks, A.E.; Assemi, S.; Tadjiki, S.; Thiagarajan, G.; Mulcock, C.; Weyrich, A.S.; Brooks, B.D.; Ghandehari, H.; Grainger, D.W. Cationic PAMAM dendrimers aggressively initiate blood clot formation. *ACS Nano,* **2012**, *6*(11), 9900-9910.

[62]   Zbinden, G.; Wunderli-Allenspach, H.; Grimm, L. Assessment of thrombogenic potential of liposomes. *Toxicology,* **1989**, *54*(3), 273-280.

[63]   Reinish, L.; Bally, M.; Loughrey, H.; Cullis, P. Interactions of liposomes and platelets. *Thromb. Haemost.,* **2008**, *60*(3), 518-523.

[64]   Nemmar, A.; Nemery, B.; Hoet, P.H.; Van Rooijen, N.; Hoylaerts, M.F. Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk. *Am. J. Respir. Crit. Care Med.,* **2005**, *171*(8), 872-879.

[65]   Casanave, E.; Tentoni, J. Comparative Fibrinolysis. In: *Fibrinolysis and Thrombolysis*; Kolev, K., Ed.; InTech: USA, **2014**.

[66]   Ware, J. Dysfunctional platelet membrane receptors: from humans to mice. *Thromb. Haemost.,* **2004**, *92*(3), 478-485.

[67]   Nemmar, A.; Yuvaraju, P.; Beegam, S.; Yasin, J.; Dhaheri, R.A.; Fahim, M.A.; Ali, B.H. *In vitro* platelet aggregation and oxidative stress caused by amorphous silica nanoparticles. *Int. J. Physiol. Pathophysiol. Pharmacol.,* **2015**, *7*(1), 27-33.

[68]   Siller-Matula, J.M.; Plasenzotti, R.; Spiel, A.; Quehenberger, P.; Jilma, B. Interspecies differences in coagulation profile. *Thromb. Haemost.,* **2008**, *100*(3), 397-404.

[69]   Shrivastava, S.; Bera, T.; Singh, S.K.; Singh, G.; Ramachandrarao, P.; Dash, D. Characterization of antiplatelet properties of silver nanoparticles. *ACS Nano,* **2009**, *3*(6), 1357-1364.

[70]   Laloy, J.; Minet, V.; Alpan, L.; Mullier, F.; Beken, S.; Toussaint, O.; Lucas, S.; Dogné, J. Impact of silver nanoparticles on haemolysis, platelet function and coagulation. *Nanobiomedicine,* **2014**, *1*(4), doi: 10.5772/59346.

[71]   Ragaseema, V.M.; Unnikrishnan, S.; Kalliyana Krishnan, V.; Krishnan, L.K. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. *Biomaterials,* **2012**, *33*(11), 3083-3092.

[72]   Martinez-Gutierrez, F.; Thi, E.P.; Silverman, J.M.; de Oliveira, C.C.; Svensson, S.L.; Vanden Hoek, A.; Sanchez, E.M.; Reiner, N.E.; Gaynor, E.C.; Pryzdial, E.L.; Conway, E.M.; Orrantia, E.; Ruiz, F.; Av-Gay, Y.; Bach, H. Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles. *Nanomedicine,* **2012**, *8*(3), 328-336.

[73]   Krajewski, S.; Prucek, R.; Panacek, A.; Avci-Adali, M.; Nolte, A.; Straub, A.; Zboril, R.; Wendel, H.P.; Kvitek, L. Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop *in vitro* assay on human blood. *Acta Biomater.,* **2013**, *9*(7), 7460-7468.

[74]   Guildford, A.L.; Poletti, T.; Osbourne, L.H.; Di Cerbo, A.; Gatti, A.M.; Santin, M. Nanoparticles of a different source induce different patterns of activation in key biochemical and cellular components of the host response. *J. R. Soc. Interface,* **2009**, *6*(41), 1213-1221.

[75]   Achilli, C.; Grandi, S.; Ciana, A.; Guidetti, G.F.; Malara, A.; Abbonante, V.; Cansolino, L.; Tomasi, C.; Balduini, A.; Fagnoni, M.; Merli, D.; Mustarelli, P.; Canobbio, I.; Balduini, C.; Minetti, G. Biocompatibility of functionalized boron phosphate (BPO$_4$) nanoparticles for boron neutron capture therapy (BNCT) application. *Nanomedicine,* **2014**, *10*(3), 589-597.

[76]   Wiwanitkit, V.; Sereemaspun, A.; Rojanathanes, R. Gold nanoparticles and a microscopic view of platelets: a preliminary observation. *Cardiovasc. J. Afr.,* **2009**, *20*(2), 141-142.

[77]   Aseychev, A.V.; Azizova, O.A.; Beckman, E.M.; Dudnik, L.B.; Sergienko, V.I. Effect of gold nanoparticles coated with plasma components on ADP-induced platelet aggregation. *Bull. Exp. Biol. Med.,* **2013**, *155*(5), 685-688.

[78]   Deb, S.; Patra, H.K.; Lahiri, P.; Dasgupta, A.K.; Chakrabarti, K.; Chaudhuri, U. Multistability in platelets and their response to gold nanoparticles. *Nanomedicine,* **2011**, *7*(4), 376-384.

[79]   Love, S.A.; Thompson, J.W.; Haynes, C.L. Development of screening assays for nanoparticle toxicity assessment in human blood: preliminary studies with charged Au nanoparticles. *Nanomedicine,* **2012**, *7*(9), 1355-1364.

[80]   Solomon, A.; Smyth, E.; Mitha, N.; Pitchford, S.; Vydyanath, A.; Luther, P.K.; Thorley, A.J.; Tetley, T.D.; Emerson, M. Induction of platelet aggregation after a direct physical interaction with diesel exhaust particles. *J. Thromb. Haemost.,* **2013**, *11*(2), 325-334.

[81]   Dobrovolskaia, M.A.; Patri, A.K.; Zheng, J.; Clogston, J.D.; Ayub, N.; Aggarwal, P.; Neun, B.W.; Hall, J.B.; McNeil, S.E. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. *Nanomedicine,* **2009**, *5*(2), 106-117.

[82]   Akchurin, G.; Akchurin, G.; Ivanov, A.; Kirichuk, V.; Terentyuk, G.; Khlebtsov, B.; Khlebtsov, N. Influence of Gold Nanoparticles on Platelets Functional Activity *In Vitro*. In: *Plasmonics in Biology and Medicine V*; Vo-Dinh, T., Lakowicz, J., Eds.; Proc. SPIE: San Jose, **2008**; Vol. *6869*, p. 68690V.

[83]   You, J.; Zhou, J.; Zhou, M.; Liu, Y.; Robertson, J.D.; Liang, D.; Van Pelt, C.; Li, C. Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated hollow gold nanospheres. *Part. Fibre Toxicol.,* **2014**, *11*, 26.

[84]   Mona, J.; Kuo, C.J.; Perevedentseva, E.; Priezzhev, A.; Cheng, C. Adsorption of human blood plasma on nanodiamond and its influence on activated partial thromboplastin time. *Diamond Relat. Mater.,* **2013**, *39*, 73-77.

[85]   Samuel, S.P.; Santos-Martinez, M.J.; Medina, C.; Jain, N.; Radomski, M.W.; Prina-Mello, A.; Volkov, Y., CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility. *Int. J. Nanomedicine,* **2015**, *10*, 2723-2734.

[86]   Dunpall, R.; Nejo, A.A.; Pullabhotla, V.S.; Opoku, A.R.; Revaprasadu, N.; Shonhai, A. An *in vitro* assessment of the interaction of cadmium selenide quantum dots with DNA, iron, and blood platelets. *IUBMB Life,* **2012**, *64*(12), 995-1002.

[87]   Vaschenko, V.I.; Samonin, V.V.; Popov, V.A.; Antonenkova, E.V.; Nikonova, V.J.; Vilyaninov, V.N.; Podvjaznikov, M.L.; Kidalov, V.N.; Titulova, T.B.; Vaschenko, T.N. Effects of fullerene C60 nanocomposites on human platelet aggregation. *Bull. Exp. Biol. Med.,* **2012**, *152*(5), 624-626.

[88]   Niwa, Y.; Iwai, N. Nanomaterials induce oxidized low-density lipoprotein cellular uptake in macrophages and platelet aggregation. *Circ. J.,* **2007**, *71*(3), 437-444.

[89]   Sokolov, A.; Aseychev, A.; Kostevich, V.; Gusev, A.; Gusev, S.; Vlasova, I. Functionalization of single-walled carbon nanotubes regulates their effect on hemostasis. *J. Phys. Conf. Ser.,* **2011**, *291*(1), 012054.

[90]   Vakhrusheva, T.V.; Gusev, A.A.; Gusev, S.A.; Vlasova, I. Albumin reduces thrombogenic potential of single-walled carbon nanotubes. *Toxicol. Lett.,* **2013**, *221*(2), 137-145.

[91]   De Paoli, S.H.; Diduch, L.L.; Tegegn, T.Z.; Orecna, M.; Strader, M.B.; Karnaukhova, E.; Bonevich, J.E.; Holada, K.; Simak, J. The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. *Biomaterials,* **2014**, *35*(24), 6182-6194.

[92]   Meng, J.; Cheng, X.; Liu, J.; Zhang, W.; Li, X.; Kong, H.; Xu, H. Effects of long and short carboxylated or aminated multiwalled carbon nanotubes on blood coagulation. *PLoS One,* **2012**, *7*(7), e38995.

[93]   Semberova, J.; De Paoli L.S.; Simakova, O.; Holada, K.; Gelderman, M.; Simak, J. Carbon nanotubes activate blood

platelets by inducing extracellular Ca^{2+} influx sensitive to calcium entry inhibitors. *Nano Lett.,* **2009,** *9,* 3312-3317.

[94]   Bircher, L.; Theusinger, O.; Locher, S.; Eugster, P.; Roth-Z'graggen, B.; Schumacher, C.; Studt, J.; Stark, W.; Beck-Schimmer, B.; Herrmann, I. Characterization of carbon-coated magnetic nanoparticles using clinical blood coagulation assays: effect of PEG-functionalization and comparison to silica nanoparticles. *J. Mater. Chem. B,* **2014,** *2,* 3753-3758.

[95]   Herrmann, I.K.; Urner, M.; Hasler, M.; Roth-Z'Graggen, B.; Aemisegger, C.; Baulig, W.; Athanassiou, E.K.; Regenass, S.; Stark, W.J.; Beck-Schimmer, B. Iron core/shell nanoparticles as magnetic drug carriers: possible interactions with the vascular compartment. *Nanomedicine,* **2011,** *6*(7), 1199-1213.

[96]   Aurich, K.; Spoerl, M.C.; Furll, B.; Sietmann, R.; Greinacher, A.; Hosten, N.; Weitschies, W. Development of a method for magnetic labeling of platelets. *Nanomedicine,* **2012,** *8*(5), 537-544.

[97]   Ali, L.M.; Gutierrez, M.; Cornudella, R.; Moreno, J.A.; Pinol, R.; Gabilondo, L.; Millan, A.; Palacio, F. Hemostasis disorders caused by polymer coated iron oxide nanoparticles. *J. Biomed. Nanotechnol.,* **2013,** *9*(7), 1272-1285.

[98]   Zhang, Y.; Liu, X.; Lu, Y.; Wang, J.; Dong, T.; Liu, X. Fabrication of heparinized mesoporous silica nanoparticles as multifunctional drug carriers. *J. Chem.,* **2013,** *2013,* (Article ID 430459).

[99]   Sanfins, E.; Augustsson, C.; Dahlback, B.; Linse, S.; Cedervall, T. Size-dependent effects of nanoparticles on enzymes in the blood coagulation cascade. *Nano Lett.,* **2014,** *14*(8), 4736-4744.

[100]   Oslakovic, C.; Cedervall, T.; Linse, S.; Dahlback, B. Polystyrene nanoparticles affecting blood coagulation. *Nanomedicine,* **2012,** *8*(6), 981-986.

[101]   Mayer, A.; Vadon, M.; Rinner, B.; Novak, A.; Wintersteiger, R.; Fröhlich, E. The role of nanoparticle size in hemocompatibility. *Toxicology,* **2009,** *258,* 139-147.

[102]   McGuinnes, C.; Duffin, R.; Brown, S.; N, Mills, L.N.; Megson, I.L.; Macnee, W.; Johnston, S.; Lu, S.L.; Tran, L.; Li, R.; Wang, X.; Newby, D.E.; Donaldson, K. Surface derivatization state of polystyrene latex nanoparticles determines both their potency and their mechanism of causing human platelet aggregation *in vitro. Toxicol. Sci.,* **2011,** *119*(2), 359-368.

[103]   Smyth, E.; Solomon, A.; Vydyanath, A.; Luther, P.K.; Pitchford, S.; Tetley, T.D.; Emerson, M. Induction and enhancement of platelet aggregation *in vitro* and *in vivo* by model polystyrene nanoparticles. *Nanotoxicology,* **2014,** 1-9.

[104]   Miyamoto, M.; Sasakawa, S.; Ozawa, T.; Kawaguchi, H.; Ohtsuka, Y. Mechanisms of blood coagulation induced by latex particles and the roles of blood cells. *Biomaterials,* **1990,** *11*(6), 385-388.

[105]   Movat, H.Z.; Weiser, W.J.; Glynn, M.F.; Mustard, J.F. Platelet phagocytosis and aggregation. *J. Cell Biol.,* **1965,** *27*(3), 531-543.

[106]   Laloy, J.; Robert, S.; Marbehant, C.; Mullier, F.; Mejia, J.; Piret, J.P.; Lucas, S.; Chatelain, B.; Dogne, J.M.; Toussaint, O.; Masereel, B.; Rolin, S. Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. *Nanotoxicology,* **2012,** *6*(2), 213-232.

[107]   Kim, D.; Finkenstaedt-Quinn, S.; Hurley, K.R.; Buchman, J.T.; Haynes, C.L. On-chip evaluation of platelet adhesion and aggregation upon exposure to mesoporous silica nanoparticles. *Analyst,* **2014,** *139*(5), 906-913.

[108]   Steuer, H.; Krastev, R.; Lembert, N. Metallic oxide nanoparticles stimulate blood coagulation independent of

their surface charge. *J. Biomed. Mater. Res. B Appl. Biomater.,* **2014,** *102*(5), 897-902.

[109]   Tavano, R.; Segat, D.; Reddi, E.; Kos, J.; Rojnik, M.; Kocbek, P.; Iratni, S.; Scheglmann, D.; Colucci, M.; Echevarria, I.M.; Selvestrel, F.; Mancin, F.; Papini, E. Procoagulant properties of bare and highly PEGylated vinyl-modified silica nanoparticles. *Nanomedicine,* **2010,** *5*(6), 881-896.

[110]   Yildirim, A.; Demirel, G.B.; Erdem, R.; Senturk, B.; Tekinay, T.; Bayindir, M. Pluronic polymer capped biocompatible mesoporous silica nanocarriers. *Chem. Commun. (Camb.),* **2013,** *49*(84), 9782-9784.

[111]   Koziara, J.M.; Oh, J.J.; Akers, W.S.; Ferraris, S.P.; Mumper, R.J. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. *Pharm. Res.,* **2005,** *22*(11), 1821-1828.

[112]   Markowicz-Piasecka, M.; Luczak, E.; Chalubinski, M.; Broncel, M.; Mikiciuk-Olasik, E.; Sikora, J. Studies towards biocompatibility of PAMAM dendrimers--overall hemostasis potential and integrity of the human aortic endothelial barrier. *Int. J. Pharm.,* **2014,** *473*(1-2), 158-169.

[113]   Dobrovolskaia, M.A.; Patri, A.K.; Simak, J.; Hall, J.B.; Semberova, J.; De Paoli Lacerda, S.H.; McNeil, S.E. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets *in vitro. Mol. Pharm.,* **2012,** *9*(3), 382-393.

[114]   Jones, C.F.; Campbell, R.A.; Franks, Z.; Gibson, C.C.; Thiagarajan, G.; Vieira-de-Abreu, A.; Sukavaneshvar, S.; Mohammad, S.F.; Li, D.Y.; Ghandehari, H.; Weyrich, A.S.; Brooks, B.D.; Grainger, D.W. Cationic PAMAM dendrimers disrupt key platelet functions. *Mol. Pharm.,* **2012,** *9*(6), 1599-1611.

[115]   Juliano, R.L.; Hsu, M.J.; Peterson, D.; Regen, S.L.; Singh, A. Interactions of conventional or photopolymerized liposomes with platelets *in vitro. Exp. Cell Res.,* **1983,** *146*(2), 422-427.

[116]   Strieth, S.; Nussbaum, C.F.; Eichhorn, M.E.; Fuhrmann, M.; Teifel, M.; Michaelis, U.; Berghaus, A.; Dellian, M. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. *Int. J. Cancer,* **2008,** *122*(2), 452-460.

[117]   Ramtoola, Z.; Lyons, P.; Keohane, K.; Kerrigan, S.W.; Kirby, B.P.; Kelly, J.G., Investigation of the interaction of biodegradable micro- and nanoparticulate drug delivery systems with platelets. *J. Pharm. Pharmacol.,* **2011,** *63*(1), 26-32.

[118]   Li, X.; Radomski, A.; Corrigan, O.I.; Tajber, L.; De Sousa Menezes, F.; Endter, S.; Medina, C.; Radomski, M.W. Platelet compatibility of PLGA, chitosan and PLGA-chitosan nanoparticles. *Nanomedicine,* **2009,** *4*(7), 735-746.

[119]   Cenni, E.; Granchi, D.; Avnet, S.; Fotia, C.; Salerno, M.; Micieli, D.; Sarpietro, M.G.; Pignatello, R.; Castelli, F.; Baldini, N. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. *Biomaterials,* **2008,** *29*(10), 1400-1411.

[120]   Bender, E.A.; Adorne, M.D.; Colome, L.M.; Abdalla, D.S.; Guterres, S.S.; Pohlmann, A.R. Hemocompatibility of poly(varepsilon-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan. *Int. J. Pharm.,* **2012,** *426*(1-2), 271-279.

[121]   Nadesh, R.; Narayanan, D.; P, R.S.; Vadakumpully, S.; Mony, U.; Koyakkutty, M.; Nair, S.V.; Menon, D. Hematotoxicological analysis of surface-modified and -unmodified chitosan nanoparticles. *J. Biomed. Mater. Res. A,* **2013,** *101*(10), 2957-2966.

[122]   Stevens, K.N.; Crespo-Biel, O.; van den Bosch, E.E.; Dias, A.A.; Knetsch, M.L.; Aldenhoff, Y.B.; van der Veen, F.H.; Maessen, J.G.; Stobberingh, E.E.; Koole, L.H. The relationship between the antimicrobial effect of catheter coatings

containing silver nanoparticles and the coagulation of contacting blood. *Biomaterials,* **2009**, *30*(22), 3682-3690.

[123] Reidy, B.; Haase, A.; Luch, A.; Dawson, K.; Lynch, I. Mechanisms of silver nanoparticle release, transformation and toxicity: a critical review of current knowledge and recommendations for future studies and applications. *Materials,* **2013**, *6*, 2295-2350.

[124] Kou, L.; Sun, J.; Zhai, Y.; He, Z. The endocytosis and intracellular fate of nanomedicines: Implication for rational design. *Asian J. Pharm. Sci.,* **2013**, *8*(1), 1-10.

[125] Meindl, C.; Kueznik, T.; Bösch, M.; Roblegg, E.; Fröhlich, E. Intracellular calcium levels as screening tool for nanoparticle toxicity. *J. Appl. Toxicol,* **2015**, *35*(10), 1150-1159.

[126] Meyer-Plath, A.; Schweinsberger, F. Nanomaterial Characterization and Metrology. In: *Nanotechnology and Human Health*; Malsch, I., Emond, C., Eds.; CRC Press: Boca Raton, **2014**.

[127] Kushida, T.; Saha, K.; Subramani, C.; Nandwana, V.; Rotello, V.M. Effect of nano-scale curvature on the intrinsic blood coagulation system. *Nanoscale,* **2014**, *6*(23), 14484-14487.

[128] Guidetti, G.F.; Consonni, A.; Cipolla, L.; Mustarelli, P.; Balduini, C.; Torti, M. Nanoparticles induce platelet activation *in vitro* through stimulation of canonical signalling pathways. *Nanomedicine,* **2012**, *8*(8), 1329-1336.

[129] Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. *Proc. Natl. Acad. Sci. U S A,* **2008**, *105*(38), 14265-14270.

[130] Dobrovolskaia, M.A.; McNeil, S.E. Understanding the correlation between *in vitro* and *in vivo* immunotoxicity tests for nanomedicines. *J. Control Release,* **2013**, *172*(2), 456-466.

[131] Santos-Martinez, M.J.; Rahme, K.; Corbalan, J.J.; Faulkner, C.; Holmes, J.D.; Tajber, L.; Medina, C.; Radomski, M.W. Pegylation increases platelet biocompatibility of gold nanoparticles. *J. Biomed. Nanotechnol.,* **2014**, *10*(6), 1004-1015.

[132] Hamad, I.; Hunter, A.C.; Szebeni, J.; Moghimi, S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. *Mol. Immunol.,* **2008**, *46*(2), 225-232.

[133] Andersen, A.J.; Windschiegl, B.; Ilbasmis-Tamer, S.; Degim, I.T.; Hunter, A.C.; Andresen, T.L.; Moghimi, S.M. Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. *Nanomedicine,* **2013**, *9*(4), 469-473.

[134] Deb, S.; Raja, S.O.; Dasgupta, A.K.; Sarkar, R.; Chattopadhyay, A.P.; Chaudhuri, U.; Guha, P.; Sardar, P. Surface tunability of nanoparticles in modulating platelet functions. *Blood Cells Mol. Dis.,* **2012**, *48*(1), 36-44.

[135] Khanbeigi, R.; Hashim, Z.; Abelha, T.; Pitchford, S.; Collins, H.; Green, M.; Dailey, L. Interactions of stealth conjugated polymer nanoparticles with human whole blood. *J. Mater. Chem. B,* **2015**, *3*, 2463-2471.

[136] Merkel, T.J.; Jones, S.W.; Herlihy, K.P.; Kersey, F.R.; Shields, A.R.; Napier, M.; Luft, J.C.; Wu, H.; Zamboni, W.C.; Wang, A.Z.; Bear, J.E.; DeSimone, J.M. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. *Proc. Natl. Acad. Sci. U S A,* **2011**, *108*(2), 586-591.

[137] Ye, W.; Shi, Q.; Hou, J.; Gao, J.; Li, C.; Jin, J.; Shi, H.; Yin, J. Fabricating bio-inspired micro/nano-particles by polydopamine coating and surface interactions with blood platelets. *Appl. Surf. Sci.,* **2015**, *351*, 236-242.

[138] Thevenot, P.; Hu, W.; Tang, L. Surface chemistry influence implant biocompatibility. *Curr. Top. Med. Chem.,* **2008**, *8*(4), 270-280.

[139] Bagatin, D.; Sturm, D.; Bagatin, T. Changes of coagulation factors in patients with carcinomas and carcinomas of the breast; perioperative influence of local anesthetics. *Period. Biol.,* **2013**, *115*(2), 299-302.

[140] Hoffmeister, H.M.; Heller, W.; Seipel, L. [Blood coagulation and fibrinolysis in arteriosclerosis]. *Z. Kardiol.,* **1999**, *88*(5), 315-323.

[141] Alzahrani, S.; Ajjan, R. Coagulation and fibrinolysis in diabetes. *Diab. Vasc. Dis. Res.,* **2010**, *7*(4), 260-273.

[142] Carr, M.E. Diabetes mellitus: a hypercoagulable state. *J. Diabetes Complicat.,* **2001**, *15*(1), 44-54.

[143] de Boer, J.D.; Majoor, C.J.; van 't Veer, C.; Bel, E.H.; van der Poll, T. Asthma and coagulation. *Blood,* **2012**, *119*(14), 3236-3244.

[144] Baccarelli, A.; Martinelli, I.; Zanobetti, A.; Grillo, P.; Hou, L.F.; Bertazzi, P.A.; Mannucci, P.M.; Schwartz, J. Exposure to particulate air pollution and risk of deep vein thrombosis. *Arch. Intern. Med.,* **2008**, *168*(9), 920-927.